Skip to main content

Genaissance, Organon to Develop Dx for Psychiatric Drug Response

NEW YORK, July 18 (GenomeWeb News) - Genaissance Pharmaceuticals and Organon will jointly study genetic markers related to drug response in certain undisclosed psychiatric disorders, and plan to develop diagnostics based on the resulting data, the companies said today.

 

Under the agreement, Organon will license Genaissance's HAP technology and will pay the company fees for genotyping samples from clinical trials and for research. Genaissance will also provide DNA isolation and sample banking for the trials.

 

In addition to providing services, Genaissance has certain rights to develop and commercialize genetic tests accompanying therapy. Both companies will share royalties on revenues generated from such tests.

 

Organon, a business unit of Akzo Nobel, is based in Roseland, NJ. It focuses on reproductive medicine, psychiatry, and anesthesia.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.